Bayer’s Kerendia, at the center of a $3 billion sales forecast, reduced the risk of cardiovascular death and heart failure in a Phase III trial.
Big Pharma has finally gotten its arms around something advocates have wanted for a long time: direct-to-consumer sales. Eli Lilly and Pfizer are leading the way.
Analysts expect the companies’ Eylea HD and Vabysmo to generate $13.2 billion between them by 2030 in the vascular endothelial growth A therapy market, as healthcare providers and patients switch from older products.
The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical’s ADHD drug Vyvanse and its generic versions by about 24% to address the medicine’s ongoing shortage in the United States.
The company’s experimental drug, azelaprag, is being developed for the treatment of obesity.
Without naming the company, the company said it has secured a commercial licence for the intellectual property necessary to commercialize GLP-1 drugs – a class of highly effective diabetes and obesity drugs – following the expiry of the originator product patents.